Koers MediPal Holdings Corporation Other OTC
Aandelen
MAHLY
US58502T1079
Farmaceutische producten
Omzet 2024 | 3.559 mld. 22,65 mld. 20,85 mld. | Omzet 2025 * | 3.607 mld. 22,95 mld. 21,13 mld. | Marktkapitalisatie | 471 mld. 3 mld. 2,76 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 | 41,47 mld. 264 mln. 243 mln. | Nettowinst (verlies) 2025 * | 34,15 mld. 217 mln. 200 mln. | EV/omzet 2024 | 0,14 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,13 x |
K/w-verhouding 2024 |
11,8
x | K/w-verhouding 2025 * |
14,2
x | Werknemers | - |
Dividendrendement 2024 |
2,59% | Dividendrendement 2025 * |
2,8% | Vrij verhandelbaar | 84,27% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shuichi Watanabe
CEO | Chief Executive Officer | 72 | 01-04-00 |
Midori Ito
CMP | Compliance Officer | - | - |
Takeshi Yanagida
CMP | Compliance Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shuichi Watanabe
CEO | Chief Executive Officer | 72 | 01-04-00 |
Toshihide Yoda
ADM | Chief Administrative Officer | 61 | 01-06-10 |
Director/Board Member | 69 | 01-04-77 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,40% | 72,89 mld. | |
-6,14% | 23,48 mld. | |
+4,65% | 8,67 mld. | |
+9,32% | 8,51 mld. | |
-25,47% | 7,71 mld. | |
+13,37% | 5,21 mld. | |
+1,58% | 4,23 mld. | |
+5,71% | 4,08 mld. | |
+1,24% | 3,99 mld. |